127 related articles for article (PubMed ID: 34238341)
21. Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19.
Li M; Yu T; Zhu J; Wang Y; Yang Y; Zhao K; Yi Y; He J; Li C; He J
Ann Palliat Med; 2021 Mar; 10(3):3307-3312. PubMed ID: 33849115
[TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.
Chen J; Lin S; Niu C; Xiao Q
Expert Rev Respir Med; 2021 Feb; 15(2):257-265. PubMed ID: 32941741
[TBL] [Abstract][Full Text] [Related]
23. [Time course of changes in cytokines (IFN-γ, IFN-α, IL-18, TNF-α) in the treatment of moderate influenza A (H1N1) pdm09 (2013-2016) with oseltamivir (Tamiflu) and umifenovir (Arbidol) alone and in combination with Kagocel].
Popov AF; Simakova AI; Dmitrenko KA; Shchelkanov MY
Ter Arkh; 2017; 89(10):66-70. PubMed ID: 29171473
[TBL] [Abstract][Full Text] [Related]
24. Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19.
Gong X; Kang S; Guo X; Li Y; Gao H; Yuan Y
BMC Infect Dis; 2021 Jun; 21(1):549. PubMed ID: 34112084
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019.
Xia Q; Dai W; Xu K; Ni Q; Li Y; Liu J; Zhao H; Guo Y; Yu L; Yi P; Su J; Lang G; Tao J; Shi D; Wu W; Wu X; Xu Y; Xu M; Yu L; Wang X; Cai H; Fang Q; Zhou J; Qiu Y; Li L
J Med Virol; 2021 Jul; 93(7):4446-4453. PubMed ID: 33448426
[TBL] [Abstract][Full Text] [Related]
26. Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission: A Preliminary Report of a Retrospective Cohort Study.
Zhang JN; Wang WJ; Peng B; Peng W; Zhang YS; Wang YL; Wan Y; Chang J; Mao L; Miao XP; Li YN; Zhou YF; Hu B
Curr Med Sci; 2020 Jun; 40(3):480-485. PubMed ID: 32474860
[TBL] [Abstract][Full Text] [Related]
27. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Rahmani H; Davoudi-Monfared E; Nourian A; Nabiee M; Sadeghi S; Khalili H; Abbasian L; Ghiasvand F; Seifi A; Hasannezhad M; Ghaderkhani S; Mohammadi M; Yekaninejad MS
Daru; 2020 Dec; 28(2):625-634. PubMed ID: 32857301
[TBL] [Abstract][Full Text] [Related]
28. Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series.
Gao W; Chen S; Wang K; Chen R; Guo Q; Lu J; Wu X; He Y; Yan Q; Wang S; Wang F; Jin L; Hua J; Li Q
Virol J; 2020 Oct; 17(1):162. PubMed ID: 33097047
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
[TBL] [Abstract][Full Text] [Related]
30. Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities.
Zhou Q; MacArthur MR; He X; Wei X; Zarin P; Hanna BS; Wang ZH; Xiang X; Fish EN
Viruses; 2020 Dec; 13(1):. PubMed ID: 33396578
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
Qu J; Li GH; Wang JJ; He GF; Huang JJ; Chen Y; Qu Q; Chen XY; Lu Q
Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):203-210. PubMed ID: 33090501
[TBL] [Abstract][Full Text] [Related]
32. Quadruple therapy for asymptomatic COVID-19 infection patients.
Wang L; Xu X; Ruan J; Lin S; Jiang J; Ye H
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):617-624. PubMed ID: 32362193
[TBL] [Abstract][Full Text] [Related]
33. Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study.
Shionoya Y; Taniguchi T; Kasai H; Sakuma N; Imai S; Shikano K; Takayanagi S; Yahaba M; Nakada TA; Igari H; Sakao S; Suzuki T
PLoS One; 2021; 16(9):e0256977. PubMed ID: 34473766
[TBL] [Abstract][Full Text] [Related]
34. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.
Xu P; Huang J; Fan Z; Huang W; Qi M; Lin X; Song W; Yi L
Microbes Infect; 2020; 22(4-5):200-205. PubMed ID: 32445881
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
Wang Z; Chen X; Lu Y; Chen F; Zhang W
Biosci Trends; 2020 Mar; 14(1):64-68. PubMed ID: 32037389
[TBL] [Abstract][Full Text] [Related]
37. [Clinical efficacy and safety of different antiviral regimens in patients with coronavirus disease 2019].
Gao X; Ma C; Ma Y; Wang X; Wei J; Feng T; Zhao G; Xu L; Zhou W; Zheng X; Zhao Q; Cao X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Dec; 32(12):1423-1427. PubMed ID: 33541491
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
39. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
40. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study.
Yu C; Zhang Z; Guo Y; Shi J; Pei G; Yao Y; Liao W; Zeng R
J Med Virol; 2021 Jan; 93(1):472-480. PubMed ID: 32621621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
